Patent Law

As a follow-up to my June 18, 2009 post, the above-titled conference will take place on October 22-23, 2009 in Philadelphia, PA and promises to help attendees effectively navigate regulations, case law, reverse payment issues and enforcement trends.

The majority of pharmaceutical antitrust issues arise from exclusion payments between brand and generic companies during patent dispute settlements. In July, the House Energy and Commerce Committee passed an amendment to America's Affordable Health Choices Act of 2009 that would prohibit reverse payment settlements between generic and brand drug companies.

In September, Senator Kohl reviewed his plans to pursue an alternate amendment to the Preserve Access to Affordable Generics Act. This would make significant changes to the proposed legislation of America's Affordable Health Choices Act.

There is some confusion for industry on what exactly is acceptable behavior regarding these antitrust issues.  At CBI's 2nd Annual Pharmaceutical Congress on Paragraph IV Disputes and Settlements hear directly from the Federal Trade Commission (FTC) on specific cases surrounding these issues.

FACULTY

• Michael P. Bauer, J.D., Ph.D., Intellectual Property Counsel, Hospira, Inc.

• Saralisa Brau, Deputy Assistant Director, Health Care Division, Federal Trade Commission
• James Burling, Partner, Antitrust Department, WilmerHale
• Mark Buscher, President, Synthon IP
• Arthur M. Dresner, Of Counsel, Duane Morris LLP
• Gloria M. Fuentes, Ph.D., J.D., Legal Director, Schering-Plough Corporation
• Robert J. Gunther, Jr., Partner, WilmerHale
• Scott Hemphill, Associate Professor, Columbia Law School
• Kurt Karst, Attorney, Hyman Phelps & McNamara, P.C.; a primary author of the FDA Law Blog
• Chad Landmon, Partner, Axinn, Veltrop & Harkrider LLP
• Geoffrey Levitt, Vice President and Chief Regulatory Counsel, Wyeth
• Gerald Masoudi, Partner, Covington & Burling LLP; Former Chief Counsel of the FDA
• Bruce Pokras, Senior Corporate Counsel, Pfizer Inc
• Pamela Politis, Ph.D., Esq., Patent Attorney, Endo Pharmaceuticals
• Cedric C.Y. Tan, Partner, Townsend and Townsend and Crew LLP
• Shashank Upadhye, Vice President and Global Head of IP, Apotex, Inc.
• Anthony J. Viola, Partner, Edwards Angell Palmer & Dodge LLP

Learn more and register here.